Tuesday, July 21	7:30 a.m. - 6:00 p.m.
7:30 a.m. - 8:00 a.m	Registration and Continental Breakfast
8:00 a.m. - 8:30 a.m.	Welcome and Introduction James H. Doroshow, M.D. Director, Division of Cancer Diagnosis and Treatment (DCTD) National Cancer Institute (NCI) National Institute of Health (NIH) Andrew N. Freedman, Ph.D. Branch Chief, Clinical and Translational Epidemiology Branch Division of Cancer Control and Population Sciences (DCCPS) National Cancer Institute (NCI) National Institute of Health (NIH)
8:30 a.m. - 8:45 a.m.	Workshop Overview and Objectives Leah B. Sansbury, Ph.D., M.S.P.H.  Program Director, Clinical and Translational Epidemiology Branch Division of Cancer Control and Population Sciences (DCCPS) National Cancer Institute (NCI) National Institute of Health (NIH)

Session I: Where are we now and where do we need to go?
8:45 a.m. - 9:15 a.m.	Cancer Pharmacogenomics: Development, Science, Translation Richard M. Weinshilboum, M.D. Chair, Division of Clinical Pharmacology Professor of Molecular Pharmacology and Experimental Therapeutics Mayo Clinic College of Medicine
9:15 a.m. - 9:45 a.m.	Challenges in the Design and Conduct of Clinical Pharmacogenomic Studies Mark J. Ratain, M.D. Leon O. Jacobson Professor of Medicine  Chairman, Committee on Clinical Pharmacology  Associate Director for Clinical Sciences, Cancer Research Center University of Chicago
9:45 a.m. - 10:00 a.m.	Coffee Break

Session II: How are we going to get there?
10:00 a.m. - 10:30 a.m.	Interventional Pharmacogenetics: Moving the Science Into Practice Howard McLeod, Pharm.D. Fred N. Eshelman Distinguished Professor Pharmacogenomics and Individualized Therapy, EshelmanSchool of Pharmacy Director, UNC Institute for Pharmacogenomics and Individualized Therapy University of North Carolina at Chapel Hill
10:30 a.m. - 11:00 a.m.	Applications of Cancer Pharmacogenomics in a Naturalistic Setting Robert S. Epstein, M.D., M.S. Chief Medical Officer, and Senior Vice President of Medical and Analytical Affairs Medco Health Solutions, Inc.
11:00 a.m. - 11:30 a.m.	Genome Guided Clinical Trials to Evaluate the Clinical Utility of Cancer Pharmacogenomics Geoffrey S. Ginsburg, M.D., Ph.D. Director, Duke Institute for Genome Sciences and Policy Duke University
11:30 a.m. - 12:00 p.m.	Panel Discussion Moderator: Richard Schilsky, M.D. Professor of Medicine Associate Dean for Clinical Research University of Chicago Panelists: Geoffrey Liu, M.D., M.Sc. Alan B. Brown Chair in Molecular Genomics Scientist, Division of Applied Molecular Oncology  Princess Margaret Hospital  University of Toronto David A. Flockhart M.D., Ph.D. Chief, Division of Clinical Pharmacology Indiana University School of Medicine   Cornelia M. Ulrich, Ph.D. Full Member FredHutchinsonCancerResearchCenter Cancer Prevention Program Seattle, WA
12:00 p.m. - 1:00 p.m.	Lunch (on your own)

Session III: Breakout Sessions
1:00 p.m. - 1:20 p.m.	Trans-NCI Pharmacogenomics and Pharmacoepidemiology Working Group (PPWG) Recommendations and Charge to the Group Andrew Freedman, Ph.D. and Leah Sansbury, Ph.D. M.S.P.H. Division of Cancer Control and Population Sciences (DCCPS) National Cancer Institute (NCI) National Institute of Health (NIH)
1:20 p.m. - 3:00 p.m.	Working Group Breakout Sessions Each breakout group will be charged to evaluate the Trans-NCI PPWG's recommendations on moving an NCI research agenda forward in the areas of pharmacoepidemiology and pharmacogenomics.   Working Group A: Group Moderators: Rochelle M. Long, Ph.D.  Chief , Pharmacological and Physiological Sciences Branch Division of Pharmacology, Physiology, and Biological Chemistry National Institute of General Medical Sciences (NIGMS) National Institute of Health (NIH) Robert L. Davis, M.D., M.P.H. Director, Center for Health Research Southeast Kaiser Permanente of Georgia   Working Group B: Moderators: Lawrence J. Lesko, Ph.D. Director, Office of Clinical Pharmacology Center for Drug Evaluation and Research Food and Drug Administration (FDA) Sheila R. Weiss Smith, Ph.D. Professor, Pharmaceutical Health Services Research Department University of Maryland, Baltimore  Working Group C Moderators: Lori M. Minasian, M.D. Chief, Community Oncology and Prevention Trials Research Branch Division of Cancer Prevention (DCP) National Cancer Institute (NCI) National Institute of Health (NIH)   Muin J. Khoury, M.D., Ph.D. Director, Office of Public Health Genomics Centers for Disease Control and Prevention (CDC)
3:00 p.m. - 3:20 p.m.	Coffee Break

Session IV: Breakout Sessions Reports
3:20 p.m. - 5:30 p.m.	Working Group Presentations and General Discussion  Working Group A: Speaker TBD  Working Group B: Speaker TBD  Working Group C: Speaker TBD
5:30 p.m. - 5:45 p.m.	Closing Remarks Andrew N. Freedman, Ph.D. Branch Chief, Clinical and Translation Epidemiology Branch Division of Cancer Control and Population Sciences (DCCPS) National Cancer Institute (NCI) National Institute of Health (NIH)
7:00 p.m.	Group Dinner at a Local Restaurant (TBD)